TGFB1 and myelodysplastic syndrome: Preclinical and clinical results indicated that TGF-β1 levels were increased in subset of MDS samples and Vactosertib treatment led to reversal of hematopoietic alteration upon exposure to MDS serum in vitro and increased blood counts in vivo [76, 77].